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Abstract
Postmortem studies have described the association between the thin-cap fibroatheroma 
(TCFA) and the occurrence of acute coronary syndrome (ACS). Both noninvasive and 
invasive techniques have been refined and used as a research tool to visualize the plaque 
at a high risk of disruption. There has been a considerable effort to develop the imag-
ing modalities that offer detailed visualization of coronary pathology and accurately 
predict the adverse cardiac outcomes. This chapter provides an overview of the current 
and experimental coronary imaging methods to detect vulnerable plaque and discuss the 
potential implication of multimodality imaging in clinical practice.
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1. Introduction
Cardiovascular diseases are the leading cause of death worldwide. It is predicted that by 
2030, the number of deaths from coronary artery disease and stroke will increase from 17.3 
million in 2008 to 23.3 million [1]. Current diagnostic strategies emphasize on preventing 
future coronary events by early identification of the vulnerable patient and modification of 
the risk by medication. The postmortem data have shown that the coronary events were asso-
ciated with sudden luminal thrombosis due to plaque rupture. The thin-cap fibroatheroma 
is the most common constituent of a vulnerable plaque. Consequently, intensive studies in 
intracoronary imaging have been conducted to demonstrate the relationship between the 
imaging findings and the cardiovascular events. However, the results from such trials remain 
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controversial. In this chapter, we summarize the currently available coronary imaging tech-
niques and the ongoing development of imaging technologies that detect vulnerable plaque. 
The clinical application of multimodalities imaging in detecting vulnerable plaque in clinic 
also discussed.
2. Definition and terminology of vulnerable plaque
The term “vulnerable plaque” has been established as a nomenclature to describe the instabil-
ity of the plaque at a high risk of disruption, leading to thrombosis and rapid stenosis progres-
sion [2–4]. Retrospective autopsy studies reported that the most common histopathological 
finding associated with plaque rupture was thin-cap fibroatheroma (TCFA), which accounted 
for 55–60%, in 30–35% plaque erosion and in 2–7% calcified nodule [5]. However, it should 
be noted that not all TCFAs will rupture, nor will all ruptures lead to a cardiac event [3], but 
disruption and healing is the mechanism of plaque growth [6] and high-grade stenosis [7]. 
Consequently, the term “vulnerable patient” has been introduced to indicate the patient who 
has a high likelihood to develop cardiac events. It remains to be investigated whether we 
should identify and treat these kinds of vulnerable lesions or patients by coronary interven-
tion before inducing clinical events.
3. Current imaging technique
3.1. Noninvasive imaging to detect vulnerable plaque
3.1.1. Coronary computed tomography angiography
Noninvasive imaging techniques could provide the unique opportunities to evaluate the 
entire coronary arteries and atherosclerotic plaque beyond luminal narrowing in single exam-
ination. Coronary computed tomography angiography (CCTA) has been intensively studied 
to establish its role for detecting vulnerable plaque and prognostic information of recurrent 
cardiovascular events.
CCTA has shown its capability to characterize plaque composition similar to intravascular 
ultrasound (IVUS) by the automated software to quantify the plaque. However, the limited 
spatial and contrast resolutions of CT preclude the detection of some histological features of 
vulnerable plaques such as fibrous cap thickness or plaque rupture [8]. Nevertheless, some 
distinct CCTA morphologies associate with high risk of acute cardiovascular events and 
should be considered as high-risk plaque: [1] large plaque volume; [2] low CT attenuation 
plaque (LAP); [3] napkin-ring sign (NRS); [4] positive remodeling (PR) and [5] spotty calcifi-
cation. The total plaque volume measured by CCTA was independently associated with the 
coronary events [9, 10]. The patients who develop acute coronary syndrome (ACS) had total 
plaque volume and total noncalcified plaque volume at baseline higher than those who did 
not develop ACS (median 94 vs. 29 mm3; P < 0.001 and 28 vs. 4 mm3; P < 0.001, respectively) 
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[9]. Low CT attenuation plaques, defined by <30 HU, were frequently observed in patients 
with ACS [11] and ruptured fibrous cap [12]. Napkin-ring sign is defined as central low-
attenuation plaque with a peripheral rim of higher CT attenuation. It has been suggested 
that napkin-ring sign is the result of differences in CT attenuation between the large necrotic 
core (a central low CT attenuation) and fibrous plaque tissue (ring-like higher attenuation) 
[13]. Presence of NRS is strongly associated with future ACS events, independent of other 
high-risk coronary CTA features (presence of obstructive plaque, positive remodeling, low-
attenuation plaque) [14], and also associated with the presence of TCFA defined by optical 
coherence tomography (OCT) [15]. Postmortem data reported that positive remodeling is 
associated with a high macrophage count and large lipid core [16]. CCTA-derived remod-
eling index has a consistent with histopathological data, lesion with positive remodeling 
(remodeling index ≥1.1) on CCTA, are associated with a higher percent of the necrotic core 
and a higher prevalence of the TCFA assessed by virtual histology intravascular ultrasound 
(VH-IVUS) than those lesions without positive remodeling [17]. In a retrospective study of 
1059 patients who underwent CCTA, patients with positive remodeling with low-attenuation 
plaques were associated with high risk of subsequent ACS  as compared to those without 
such features. (HR: 22.8, 95% CI: 6.9 to 75.2, p < 0.001) [9]. Spotty calcification on CCTA is 
defined as a small, dense (>130 HU) plaque component surrounded by noncalcified plaque 
tissue and size <3 mm. Small spotty calcification (< 1 mm) was related to vulnerable plaque 
features defined by VH-IVUS [18]. From all of the above features, CCTA would be considered 
as a tool to detect vulnerable plaque in the future.
3.1.2. Cardiac magnetic resonance (CMR) imaging
Compared with CCTA, cardiac magnetic resonance (CMR) identifies coronary stenosis >50% 
comparable to CCTA [19] where it could provide a superior in defining soft tissue such as 
positive remodeling and increased coronary wall thickness [20]. High-intensity coronary sig-
nal on T1-weighted MRI is associated with vulnerable morphology [21, 22] and future cardiac 
events. It has been demonstrated that high-intensity signal is related to the formation of met-
hemoglobin during subclinical plaque rupture or hemorrhage [23]. T2-weighted short inver-
sion recovery sequences have shown their ability to detect coronary wall edema relating to 
culprit ACS lesions [24]. However, coronary assessment by CMR is hampered by an inherent 
susceptibility to motion artifact from prolonged acquisition time [25] that limits its applica-
tion in clinical practice.
3.1.3. Combined positron emission tomography (PET)-CCTA
Despite the fact that CCTA and MRI demonstrate morphological characterization of plaque, 
they could not quantify the degree of plaque inflammation. The positron emission tomography 
(PET) has been combined with computed tomography to identify the anatomical and degree 
of inflammation. Although 18F–fluorodeoxyglucose (FDG) is acknowledged as conventional 
tracer in this field, it is hampered by significant myocardium uptake [26] and arterial wall with 
inflammation. To avoid the myocardial metabolism artifact, 18F–sodium fluoride (NaF) has 
been introduced to circumvent the myocardial uptake issue. 18F–NaF could localize individual 
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coronary plaque with minimal background uptake. 18F–NaF is a useful tool to detect molecu-
lar calcification which closely linked to plaque rupture. It also provides reliable identification 
and localization ruptured and high-risk coronary plaque in post-MI setting [27]. The ongoing 
trials (PREFFIR, NCT02278211 and NCT02110303) aim to investigate the prognostic value of 
18F–NaF coronary microcalcification to predict the progression and recurrent of events.
3.2. Invasive imaging to detect vulnerable plaque
3.2.1. IVUS and its derivatives
3.2.1.1. Grayscale IVUS
Grayscale IVUS (GS-IVUS) provides robust information of vessel dimension, lumen dimen-
sion, phenotype and distribution of the plaque. GS-IVUS has been incorporated in the guide-
line as a supporting tool to guide percutaneous coronary intervention in selected lesions 
[28]. It has been reported that increase plaque burden is associated with adverse cardiovas-
cular outcomes [29]. The major drawback of GS-IVUS is the imprecision to detect lipid-rich 
plaque which is a marker of the plaque vulnerability [30]. Several GS-IVUS features have been 
reported that they linked to high risk for cardiovascular events: Echo-attenuated plaque was 
identified by the absence of the ultrasound signal behind plaque that was either hypoechoic 
or isoechoic to the reference adventitia without calcification [31]. This feature indicated the 
presence of a large NC or lipid pool, and the closer the attenuation was to the lumen, the more 
advanced of NC [32]. Echolucent plaque contained an intraplaque zone of absent or low echo-
genicity surrounded by tissue of greater echodensity. Echolucent zone indicated the presence 
of a relatively smaller NC or lipid pool compared with echo-attenuated plaque [32]. Spotty 
calcification contained small calcium deposits within arcs of <90°. IVUS spotty calcification is 
closely related to the presence of an NC, also indicating plaque instability [32].
Besides the ability to demonstrate plaque morphology, IVUS was fused with the coronary 
angiography to reconstruct the blood flow simulation model to examine the local hemody-
namic forced on coronary plaque progression. The PREDICTION (Prediction of Progression 
of Coronary Artery Disease and Clinical Outcome Using Vascular Profiling of Shear Stress 
and Wall Morphology) Study, which is done in 374 patients with ACS, showed that the large 
plaque burden and low local endothelial shear stress (ESS) are independent predictor of 
plaque progression and lumen narrowing with positive predictive value of 41% [33].
3.2.1.2. Virtual histology intravascular ultrasound
Due to the limited ability of IVUS to determine the composition of plaque, the IVUS radiofre-
quency analysis (virtual histology, VH) has been introduced to characterize the plaque com-
ponents. The main difference between GS-IVUS and VH-IVUS is that the GS-IVUS imaging is 
formed by the envelope (amplitude) of the radiofrequency signal, whereas VH-IVUS analysis 
uses several additional spectral parameters to identify four tissue types [34, 35]: fibrous (dark 
green), fibrofatty (yellow-green), necrotic core (red) and dense calcium (white). VH-IVUS-
derived TCFA is defined by necrotic core-rich (>10% of the cross-sectional area) plaque being 
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in contact with the lumen and with a percent plaque volume of 40% seen on at least three 
consecutive images [36]. The Providing Regional Observations to Study Predictors of Events 
in the Coronary Tree (PROSPECT) trial [37] reported the efficacy of VH-IVUS in predict-
ing lesions that will progress and cause cardiovascular events in 697 patients with ACS. The 
investigators reported that plaque burden of 70% or greater, minimal lumen area of 4.0 mm2 
or less, and TCFA phenotype were associated with recurrent events after a median of 3.4 years 
of follow-up with a positive predictive value of 18.2%. The similar trend was reported in VIVA 
(VH-IVUS in Vulnerable Atherosclerosis) trial, and nonculprit TCFA phenotype was associ-
ated with nonrestenotic MACE, on both individual plaque and whole-patient analysis [38].
3.2.1.3. Intravascular ultrasound near-infrared spectroscopy
Near-infrared spectroscopy is an analytical technique that is used in science and industry to 
determine the chemical composition of substances [39]. A sample of interest is illuminated 
with near-infrared (NIR) light (800–2500 nm in wavelength) which is absorbed by C–H, O–H 
and N–H bonds. Each given molecule has a unique pattern of absorption known as its spectro-
scopic fingerprint. Therefore, NIRS could provide sample recognition and tissue classification 
[40]. NIRS has been applied to the catheter-based device to identify and quantify lipid cores 
which is the major composition of the TCFA, the most common type of vulnerable plaque 
[5]. In addition, NIRS can image through calcium, whereas conventional IVUS, VH-IVUS 
and OCT are not capable. The current intravascular ultrasound near-infrared spectroscopy 
(IVUS-NIRS) catheter, TVC Imaging System™ (InfraRedx Inc. Burlington, MA, USA), is CE 
(Conformité Européenne) marked and has an FDA clearance for lipid core-containing coro-
nary plaques (LCP) detection. The information from the catheter will be processed via math-
ematical algorithm that predicts the probability of vulnerable plaque and are displayed 
on a chemogram, with lipid pools colored yellow in a background of red [39]. The “block 
chemogram” provides visual interpretation of the algorithm probability from zero to one 
for likelihood of LCP in the corresponding 2-mm chemogram segment (yellow P > 0.98, tan 
0.84 ≤ P ≤ 0.98, orange 0.57 ≤ P < 0.84 and red P < 0.57) [3]. The lipid core burden index (LCBI) 
represents the lipid burden in a vessel segment. LCBI is the fraction of valid pixels within the 
scanned region that exceed an LCP probability of 0.6 per million (%, multiplied by 1000) [40]. 
The maxLCBI
4 mm
 indicates sites of high lipid accumulation and is defined as the LCBI of the 
most lipid-rich 4-mm area within the segment of interest [39]. It should be noted that NIRS 
could provide only information about lipid core plaque, but it is not able to evaluate the depth 
and the volume of lipid core.
The autopsy-based study has shown that catheter-based NIRS system accurately identified 
LCP and IVUS-NIRS system significantly improved the sensitivity for detecting a histological 
fibroatheroma, especially in calcified lesions and lesions with a smaller plaque burden [41]. 
The data from diabetic/hypercholesterolemic animal model showed that IVUS-NIRS imaging 
detected and predicted future development of high-risk coronary lesions such as increased 
plaque and necrotic core areas, thinned fibrous cap, increased concentration of activated 
inflammatory cells and apoptotic cells within the fibrous cap [42, 43]. Recently, Oemrawsingh 
et al. has reported that coronary LCBI in patients with stable angina pectoris (SAP) or acute 
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coronary syndrome (ACS) is associated with 1-year adverse cardiovascular events through-
out the entire coronary tree and not necessarily at the imaged segment or a lesion-specific 
risk [44]. Madder et al. reported that detection of LRP at nonstented sites was also associ-
ated with an increased risk of future major adverse cardiovascular events [45]. The ongoing 
PROSPECT II (NCT02171065), the Lipid-Rich Plaque (NCT02033694) [46] and ORACLE-NIRS 
(NCT02265146) will support the concept of vulnerable patient identification and may improve 
a better care in such patients.
3.2.1.4. Intravascular photoacoustic imaging
Intravascular photoacoustic imaging (IVPA) is an analytic technique, which is highly spe-
cific for lipid type. The principle of photoacoustics is based on the optical contrast which is 
provided by the differences in the absorption spectra of plaque components to image plaque 
composition [47], like NIRS. However, it has depth resolution, which makes IVPA possible 
to know the exact spatial location of the lipids within the plaque relative to the lumen border 
[47]. Lipid in the plaque mainly consists of cholesterol and cholesterol esters, whereas pericar-
dial fat is stored as mixture of fatty lipid. IVPA could differentiate between lipid in the plaques 
and periadventitial fat. It is postulated that this modality would offer detailed assessment of 
plaque vulnerability and evaluation of the pharmacologic plaque modulation in future clini-
cal studies. However, the hurdle of IVPA is that the image quality drastically deteriorates in 
the presence of the luminal blood that may require blood clearance during image acquisition 
[47]. The clinical application of IVPA remains to be demonstrated in clinical studies.
3.2.2. Optical coherence tomography and its derivatives
3.2.2.1. Optical coherence tomography
OCT uses low-coherence, near-infrared light (1.3 μm wavelength) emitted through a fiber optic 
wire with rotating lens [48]. The image is created based on reflection time and the intensity of 
the backscattered light [49]. The resolution of OCT image (10–20 μm axial and 20–40 μm lateral) 
allows precise visualization of the plaque morphology [48, 50]. It also enables the measurement 
of fibrous cap thickness [51, 52]. Another unique ability of OCT is identification of macrophages, 
which are relatively large (20–50 μm) [53], neovascularization [54–56] and microcalcifications [48].
Due to its limited tissue penetration (1–3 mm), it remains impossible to precisely assess the 
deeper layers behind light-attenuating plaques and thus accurate plaque volume. The imaging 
artifacts also lead to the misclassification of the stable plaque type to high-risk plaque type. For 
instance, tangential artifact can mimic superficial accumulation of macrophages or necrotic core 
[48, 57]. It has been demonstrated that not all bright spots are caused by macrophages and only 
23% of bright spots represent macrophages. Other sources of bright spots can be generated by 
a combination of plaque components that create sharp changes in the index of refraction [58].
Besides the direct assessment of the plaque morphology, OCT also allows vascular profiling 
of coronary arteries that enables microenvironment study within the coronary arteries [59]. 
The advancement of computed fluid dynamic (CFD) in combination with precise OCT images 
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extends our current understanding of endothelial shear stress (ESS). OCT-based assessment 
of local ESS in nonculprit arterial regions of 21 patients presenting with acute coronary syn-
drome has shown that segments with low ESS (< 1 Pa) had higher prevalence of lipid-rich 
plaques (37.5 vs. 20.0%; P = 0.019) and thin-cap fibroatheroma (12.5 vs. 2.0%; P = 0.037) com-
pared with segments with higher ESS (≥ 1 Pa) [60]. Additionally, areas with low ESS as com-
pared to those with high ESS showed larger lipid accumulation, thinner fibrous cap, and 
greater macrophage density, which would contribute to plaque vulnerability [60].
3.2.2.2. Optical coherence tomography and near-infrared spectroscopy
Although OCT could provide excellent image resolution, its limitation is the light penetration 
depth and the capability to detect the plaque composition. The optical coherence tomography 
and near-infrared spectroscopy (OCT-NIRS) system utilizes a wavelength-swept light source 
for both OCT and NIRS. The catheter collects the backscattered OCT light together with the 
chemical substances from the plaque residing within the arterial wall [61]. Therefore, it will 
eliminate the uncertainty of plaque-type interpretation and will facilitate identification of the 
high-risk plaque location.
3.2.2.3. Optical coherence tomography and near-infrared autofluorescence (OCT-NIRAF)
Several intracoronary imaging methods have been developed to visualize plaque. However, 
those techniques could not provide the status of inflammation. Therefore, the molecular 
imaging of atherosclerosis has been studied to address the inflammatory activity, macro-
phage composition, presence of fibrin, cellular apoptosis and neoangiogenesis [62]. One of the 
molecular imaging-based approaches is near-infrared fluorescence (NIRF) [63]. The NIRF can 
detect the deposition of the indocyanine green (an FDA-approved NIRF-emitting compound) 
in lipid-rich and atherosclerotic plaques [64].
Due to the requirement of exogenous agent in NIRF technique, the “near-infrared autofluores-
cence (NIRAF)” has been developed to detect fluorescence from naturally occurring molecules. 
It has been reported that the combination of OCT and red-excited NIRAF (633 nm) with emis-
sion detected between 700 and 900 nm can be used to detect necrotic core and TCFA in cadaver 
coronary arteries [65]. Recently, Ughi et al. report the first-in-man study of optical coherence 
tomography and near-infrared autofluorescence (OCT-NIRAF) in 12 patients undergoing per-
cutaneous coronary intervention. They showed that OCT-NIRAF was as safe as conventional 
OCT in terms of the capability to provide automatic and facilitated image interpretation [66].
3.2.2.4. OCT light property analysis
Despite the excellent resolution of OCT, the image interpretation of plaque morphology based 
on qualitative criteria can be ambiguous and time-consuming. To overcome those limitations, 
the automatic classification of atherosclerotic plaque and quantitative assessment of tissue 
characteristics with OCT light property analysis are investigated. Light property has three 
components: light intensity, light attenuation and backscatter. The light intensity indicates the 
amount of light signal detected at a certain location in the vessel wall based on reflection and 
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backscatter. The light attenuation, estimated as the depth-resolved attenuation coefficient, 
indicates how fast the light signal decays. It is the rate of exponential decreasing intensity 
related to the light propagation depth. The backscatter, estimated as the depth-resolved back-
scattering coefficient, is related to the efficiency of light scattering in the tissue [67].
In ex vivo validation experiments, highly attenuating regions (attenuation coefficient μ
t
 ≥ 8 mm−1) 
have been associated with necrotic core or macrophages. Conversely, low attenuating regions 
μ
t
 < 6 mm−1 were associated with healthy vessel, intimal thickening or calcified plaque [68, 69]. 
Thus, by using light attenuation analysis, it could detect the lipid-rich plaque component.
Liu and colleagues extended the light property analysis with light intensity and backscatter 
in addition to the light attenuation analysis [67]. They evaluated the light property values in 
each tissue type (fibrous, lipid, calcium, calcium with lipid, macrophages and necrotic core) 
in histology-matched OCT images and found that all tissue types have their own spectrum of 
light property, suggesting the possibility of automatic tissue characterization with OCT light 
property analysis in the near future.
4. Clinical application of multimodality imaging in detecting vulnerable 
plaque
4.1. Assessment of the effect of pharmacotherapy on plaque modulation
OCT has been used to evaluate the plaque stability by statin therapy, and an increase in 
fibrous cap thickness in coronary plaques was observed after the treatment [70, 71]. Recently, 
IVUS has been used to evaluate the effect of proprotein convertase subtilisin kexin type 9 
(PCSK9) inhibitors on the progression of coronary atherosclerosis in statin-treated patients. 
PCSK9 inhibition with evolocumab was associated with a reduction in percent atheroma vol-
ume for evolocumab (−0.95%) but not placebo (+0.05%) and a greater percentage of patients 
demonstrating plaque regression (64.3 vs. 47.3%) [72].
4.2. Assessment of the effect of local therapy on vulnerable plaque
Previously, bioresorbable scaffold (BRS) has been investigated for the capability of sealing 
superficial plaque [73–75]. The neointima on top of the BRS struts altered the plaque phe-
notype by covering the calcific spots and TCFA, thus transforming the TCFA to thick-cap 
fibroatheromas that associate with the plaque stability without compromising the luminal 
dimensions [73]. It has been speculated that BRS may prevent the cardiac adverse event 
by invasive sealing of the high risk to rupture plaques. The ongoing PROSPECT ABSORB 
(NCT02171065) trial will examine the treatment of vulnerable plaques with the ABSORB 
bioresorbable vascular scaffold (BVS) plus guideline-directed medical therapy (GDMT) in 
comparison with GDMT alone [76]. All randomized patients will undergo 2-year follow-
up angiography with three-vessel repeat NIRS-IVUS imaging, thus enabling evaluation of 
plaque regression/progression in intervening vessels and nonintervening vessels [77]. The 
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SECRITT-II study will investigate the ability of BVS to expedite the process of de novo fibrous 
cap formation in comparison with high-dose statin therapy [77].
5. Future perspective
Aside from the technical issues and validity of each imaging modality in detecting vulnerable 
plaque, and predicting the future events, a real question is whether identification of vulner-
able plaque would have any impact on our practice [78–80]. Although it has been demon-
strated that VH-IVUS TCFA is able to predict recurrence of events, the positive predictive 
value was 18% [37] with the risk of catheter-related complication of 0.6–1.6% [33, 37]. Thus, 
the improvement of imaging technologies is required to provide complete and detailed evalu-
ation of plaque morphology, physiology, and biology to predict the future events [81]. New 
hybrid catheters have shown their capabilities in demonstrating the plaque vulnerability; 
however, the clinical benefit needs confirmation by larger studies. Noninvasive technique, 
especially CCTA combined with PET, may support the detection of vulnerable plaque and 
tailoring the treatment of those patients.
6. Conclusion
Either noninvasive or invasive imaging techniques have their unique properties in detect-
ing the vulnerable plaque; however, none of the individual imaging techniques is able to 
provide complete plaque assessment. There has been a considerable effort to develop the 
imaging modalities that offer detailed visualization of coronary pathology and accurately 
predict the adverse cardiac outcomes. Combination of imaging techniques in single exami-
nation would provide mechanistic insight into the development and pathophysiology of 
the vulnerability of the plaque. To translate imaging information into clinical application, 
it requires randomized trials investigating whether interventions according to the imaging 
findings can improve clinical outcomes, along with an intensifying improvement of imag-
ing technologies.
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CCTA  Coronary Computed Tomography Angiography.
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LCB  Lipid Core Burden Index.
LCP  Lipid Core-containing coronary Plaques.
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